Educational Content: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for diagnosis and treatment.

Kanjinti vs. Ogivri: Comparison

Medically reviewed by Min Clinic Staff | Updated: January 2026

Are Kanjinti and Ogivri the Same Thing?

Kanjinti (trastuzumab-anns) and Ogivri (trastuzumab-dkst) are HER2/neu receptor antagonists indicated for the treatment of HER2 overexpressing breast cancer and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Side effects of Kanjinti and Ogivri that are similar include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough, rash, low white blood cell count (neutropenia), fatigue, anemia, inflammation of the mouth and lips, weight loss, upper respiratory tract infections, low blood platelets (thrombocytopenia), mucosal inflammation, runny or stuffy nose, and changes in taste.

Both Kanjinti and Ogivri may interact with anthracycline.

What Are Possible Side Effects of Kanjinti?

Side effects of Kanjinti include:

  • headache,
  • diarrhea,
  • nausea,
  • chills,
  • fever,
  • infection,
  • congestive heart failure,
  • insomnia,
  • cough,
  • rash,
  • low white blood cell count (neutropenia),
  • fatigue,
  • anemia,
  • inflammation of the mouth and lips,
  • weight loss,
  • upper respiratory tract infections,
  • low blood platelets (thrombocytopenia),
  • mucosal inflammation,
  • runny or stuffy nose,
  • changes in taste

This is not a complete list of side effects, and others may occur.

What Are Possible Side Effects of Ogivri?

Common side effects of Ogivri include:

  • headache,
  • diarrhea,
  • nausea,
  • chills,
  • fever,
  • infection,
  • congestive heart failure,
  • insomnia,
  • cough,
  • rash,
  • low white blood cell count (neutropenia),
  • fatigue,
  • anemia,
  • swelling and sores inside the mouth,
  • weight loss,
  • upper respiratory tract infections,
  • low platelet count (thrombocytopenia),
  • mucosal inflammation,
  • runny or stuffy nose,
  • and changes in taste.

What is Kanjinti?

Kanjinti (trastuzumab-anns) is a HER2/neu receptor antagonist indicated for the treatment of HER2 overexpressing breast cancer and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

What is Ogivri?

Ogivri (trastuzumab-dkst) is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

What Drugs Interact With Kanjinti?

Kanjinti may interact with anthracycline. Tell your doctor all medications and supplements you use. Kanjinti is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Kanjinti and for 7 months following the last dose. It is unknown if Kanjinti passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

What Drugs Interact With Ogivri?

Ogivri may interact with anthracycline. Tell your doctor all medications and supplements you use. Ogivri is not recommended for use during pregnancy; it may harm a fetus. Use effective contraception during treatment with Ogivri and for 7 months following the last dose. It is unknown if Ogivri passes into breast milk. Consult your doctor before breastfeeding.

Tell your doctor all medications and supplements you use.

How Should Kanjinti be Taken?

The dose and regimen of Kanjinti depends on the condition being treated.

How Should Ogivri be Taken?

Dose of Ogivri depends on the condition being treated.